IBI 354
Alternative Names: IBI-354; Recombinant Anti-HER2 monoclonal Antibody-Camptothecin derivative conjugateLatest Information Update: 23 Sep 2024
At a glance
- Originator Innovent Biologics
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 18 Sep 2024 Efficacy and adverse event data from phase I/II trial in Solid tumours was released by company
- 22 Feb 2024 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Inoperable/Unresectable, Late-stage disease) in Australia (Parenteral) before February 2024 (NCT05636215) (Innovent Biologics pipeline, February 2024)
- 09 Dec 2022 Innovent-Biologics plans a phase I/II trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Australia (Parenteral) in January 2023 (NCT05636215)